All In Biotech

NDA 021770 · Abbvie

Alphagan P

Brimonidine Tartrate · Ophthalmic

Last checked: Nov 20, 2026Latest source record: Sep 18, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2005

Aug 19, 2005

Approved uses

1

Original approval plus efficacy supplements

Registered trials

177

44 Phase 3, 5 recruiting

FAERS reports

9,475

4,593 serious, 491 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Sep 18, 2025.

ALPHAGAN P (brimonidine tartrate ophthalmic solution) 0.1% or 0.15% is indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. ALPHAGAN P is an alpha adrenergic agonist indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. ( 1 )

Mechanism: ALPHAGAN P is a relatively selective alpha-2 adrenergic receptor agonist with a peak ocular hypotensive effect occurring at two hours post-dosing. Fluorophotometric studies in animals and humans suggest that brimonidine tartrate has a dual mechanism of action by reducing aqueous humor production and increasing uveoscleral outflow.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • ALPHAGAN P · BRIMONIDINE TARTRATE 0.1% · SOLUTION/DROPS, OPHTHALMIC · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Brimonidine" as an intervention, any sponsor and status, largest first.

All 177 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • eye pain602
  • eye irritation599
  • drug ineffective591
  • ocular hyperaemia574
  • fatigue464
  • vision blurred458
  • intraocular pressure increased397
  • off label use395
  • dizziness374
  • headache374
  • diarrhoea300
  • dyspnoea298

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200440
200556
200655
200774
200859
2009126
201085
2011127
2012232
2013255
2014406
2015654
2016754
2017721
2018638
2019691
2020837
2021547
2022576
2023598
2024619
2025633
2026692

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Alphagan P (Brimonidine Tartrate)

2024 spending

$92.7M

Beneficiaries

69,323

256,839 claims

Per beneficiary

$1,337

$37.44 per unit

View as table
YearSpending
2020$204,587,977
2021$202,241,701
2022$201,793,298
2023$181,159,172
2024$92,661,674

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 312 on PubMed

Sponsor: AbbVie

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.